WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Hims & Hers falls 8% after Novo's legal threat. Here's the latest

Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"

Raccontata dacnbc.comft.comfortune.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
cnbc.comStai leggendo4 mesi fa

Hims & Hers falls 8% after Novo's legal threat. Here's the latest

Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"

originale
fortune.com4 mesi fa

Hims & Hers scraps copycat Wegovy weight-loss pill after probe | Fortune

The announcement comes a day after the US Food and Drug Administration said it was cracking down on copycat weight-loss treatments.

Leggi questa versione → originale
ft.com4 mesi fa

Hims & Hers abandons copycat weight-loss drug in face of FDA probe

Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 5 febbraio 2026·cnbc.com

    Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill

    Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149 Novo sells the branded pill for.

  2. giovedì 5 febbraio 2026·ft.com

    Novo Nordisk hits out at rival Hims & Hers over cheaper weight-loss pill

    US telehealth group will sell product for $49 a month, a third that of its Danish competitor

  3. venerdì 6 febbraio 2026·cnbc.com

    Hims & Hers falls 8% after Novo's legal threat. Here's the latest

    Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"

  4. sabato 7 febbraio 2026·cnbc.com

    US signals crackdown on compounded weight-loss drugs; Hims shares tumble

    The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

  5. sabato 7 febbraio 2026·ft.com

    Hims & Hers abandons copycat weight-loss drug in face of FDA probe

    Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy

  6. sabato 7 febbraio 2026·cnbc.com

    Hims & Hers pulls copycat weight-loss pill after threats of legal action

    Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal action.

  7. sabato 7 febbraio 2026·fortune.com

    Hims & Hers scraps copycat Wegovy weight-loss pill after probe | Fortune

    The announcement comes a day after the US Food and Drug Administration said it was cracking down on copycat weight-loss treatments.

  8. lunedì 9 febbraio 2026·cnbc.com

    Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill

    Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.